LOTTE (004990) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
14 Aug, 2026Executive summary
Consolidated revenue for H1 2026 was KRW 15.54 trillion, with operating income of KRW 175.1 billion and net income of KRW 78.8 billion, marking a return to profitability after losses in the previous two years.
The group operates across retail, chemicals, food, and bio, with 83 consolidated subsidiaries and a diversified business portfolio.
Major capital market activities included significant bond and hybrid security issuances, with robust liquidity and compliance with all debt covenants.
Financial highlights
H1 2026 revenue: KRW 15.54 trillion; operating income: KRW 175.1 billion; net income: KRW 78.8 billion.
Total assets: KRW 23.65 trillion; total equity: KRW 9.89 trillion; total liabilities: KRW 13.76 trillion.
Debt-to-equity ratio: 139.1% (well below covenant limits).
Cash and cash equivalents: KRW 1.24 trillion.
H1 2026 EPS: KRW 330 (basic, common stock).
Outlook and guidance
Management targets continued revenue growth and margin improvement, with a focus on high-value segments such as specialty chemicals, battery materials, and bio CDMO.
Ongoing investments in capacity expansion, digital transformation, and ESG initiatives are expected to support long-term competitiveness.
Latest events from LOTTE
- Operating profit surged 156% year-over-year as F&B growth offset retail restructuring.004990
Q1 2026 - 4Q25 saw stable revenue, wider operating loss, improved net loss, and higher shareholder returns.004990
Q4 2025 - Targeting 35%+ shareholder return rate and growth via new businesses and ESG leadership.004990
Corporate Value-up Plan presentation - H1 2025: Revenue KRW 15.76T, net loss KRW 160.4B, debt ratio 149.4%, positive 2H25 outlook.004990
Q2 2025 - Record sales offset by profit decline from higher costs and affiliate losses; growth plans continue.004990
Q4 2024 - H1 2024 saw record revenue but a net loss due to equity losses and chemical headwinds.004990
Q2 2024 - Record revenue but net loss due to cost pressures; major biologics investments continue.004990
Q3 2024 - Revenue fell 4.1% YoY to KRW 3.59 trillion, with a net loss of KRW 91.87 billion.004990
Q1 2025 - 3Q25 revenue was KRW 4,154B, with a net loss of KRW -283.9B and a 156.1% debt ratio.004990
Q3 2025